Online inquiry

IVTScrip™ mRNA-Anti-MUC16, DMUC5754A(Cap 0, 5-Methoxy-UTP, 120 nt-poly(A))   (CAT#: GTTS-WQ6667MR)

This product GTTS-WQ6667MR is a type of mRNA having 120 nt poly(A) tail and modified with Cap 0 & 5-Methoxy-UTP. It ecodes the monoclonal antibody that targets MUC16 gene. The antibody can be applied in Ovarian Cancer research.
Specifications
Product type mRNA
Modified bases 5-Methoxy-UTP
5' Cap Cap 0
Species Humanized
RefSeq NM_001018016.3
Applications Gene therapy research
Format Powder
Quantity 100 µg
Purification oligo-dT affinity purification
Target Gene
Gene ID 4582
UniProt ID P15941
Download
Download resources about mRNA therapeutics development to boost your research.
CUSTOMER REVIEWS and Q&As

There are currently no Customer reviews or questions for IVTScrip™ mRNA-Anti-MUC16, DMUC5754A(Cap 0, 5-Methoxy-UTP, 120 nt-poly(A)) (GTTS-WQ6667MR). Click the button above to contact us or submit your feedback about this product.
See other products
CAT Product Name Product Type CDs
GTTS-WQ8055MR IVTScrip™ mRNA-Anti-CD33, h2H12ec(Cap 0, N1-Methylpseudo-UTP, 120 nt-poly(A)) mRNA h2H12ec
GTTS-WQ2273MR IVTScrip™ mRNA-Anti-C5, ALXN1007(Cap 0, N1-Methylpseudo-UTP, 30 nt-poly(A)) mRNA ALXN1007
GTTS-WQ11890MR IVTScrip™ mRNA-Anti-GUCY2C, MLN-0264(Cap 1, Pseudo-UTP, 120 nt-poly(A)) mRNA MLN-0264
GTTS-WQ7817MR IVTScrip™ mRNA-Anti-GLP1R, GSK 716155(Cap 0, N1-Methylpseudo-UTP, 30 nt-poly(A)) mRNA GSK 716155
GTTS-WQ15421MR IVTScrip™ mRNA-Anti-LAG3, TSR-033(Cap 0, 5-Methyl-CTP & Pseudo-UTP, 30 nt-poly(A)) mRNA TSR-033
GTTS-WQ9186MR IVTScrip™ mRNA-Anti-FOLR1, IMGN853(Cap 1, N1-Methylpseudo-UTP, 30 nt-poly(A)) mRNA IMGN853
GTTS-WQ9414MR IVTScrip™ mRNA-Anti-PTPRC, Iomab-B(Cap 1, 2-Thio-UTP, 30 nt-poly(A)) mRNA Iomab-B
GTTS-WQ12210MR IVTScrip™ mRNA-Anti-TNFRSF4, MOXR-0916(Cap 1, Pseudo-UTP, 120 nt-poly(A)) mRNA MOXR-0916
All products and services are For Research Use Only and CANNOT be used in the treatment or diagnosis of disease.
webinar

EABR Nanoparticles as a Platform Technology for Hybrid mRNA Vaccine Development

November 20th, 2024, 2 PM–3 PM EST

REGISTER NOW